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ABSTRACT
CHARACTERIZATION OF THE RANK LIGAND POSITIVE GIANT CELL
FOUND IN THE IN THE INTERFACIAL MEMBRANE
By Patrick Jones, B.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Director: Dr. Matthew J. Beckrnan
Assistant Professor, Department of Biochemistry

Aseptic osteolysis is a major complication to total joint arthroplasty requiring
several thousand people a year to have to undergo revisions of their joint prosthesis. The
formation of the interfacial membrane has been associated with aseptic osteolysis leading
to the failure of all types of total joints. Recent evidence suggests that RANKL, a potent
activator of bone reabsorption, is present in the interfacial membrane. Prior research in
this laboratory to determine the source of RANKL in the interfacial membrane has
revealed the presence of intense areas of RANKL concentration in the membrane. These
areas of RANKL concentration correspond to multiple nuclei and a distinct cellular
structure in the tissue as determined through light microscopy. This structure either
represents a multi-nucleated giant cell or a cluster of cells that express high
concentrations of RANKL. These following studies attempted to characterize this cell
and determine its lineage.

The results of these studies show that the RANIU producing anomaly appears
multi-nucleated in all examples with a RANKL staining pattern that makes it appear as a
multi-nucleated cell. Furthermore this RANIU positive giant cell (RPGC) stains negative
for markers typically seen on myeloid cells, osteoclasts, and osteoblasts. This RPGC does
however stain very well for fibroblast markers and the inflammatory cytokines TNF-a,
IL- 1P, and IL-6. The most interesting result from these studies revealed that this cell was
positive for cytomegalovirus and expressed high concentrations of TNF-a converting
enzyme (TACE). These data does lead to a hypothesis as to how this cell might form and
how large an impact it might play in the interfacial membrane with respect to aseptic
bone reabsorption.

GENERAL INTRODUCTION

Aseptic Osteolysis
There are approximately 1.5 million joint replacement surgeries performed every
year and total joint replacement is widely regarded as one of the most successful surgical
procedures in medicine today [I]. However a condition known as aseptic osteolysis has
become a major complication to the long term outcome of these joint replacement
surgeries. According to a retrospective study conducted between 1996 and 2003, of 439
revision hip surgeries done nearly 70% percent of them were due to periprosthetic
osteolysis leading to aseptic loosening [2]. The process of periprosthetic osteolysis is
defined as the progressive destruction of periprosthetic bony tissue, characterized on
serial radiographs as progressive radiolucent lines and cavitations at the implant of
cement-bone interface [3]. This disease take place in the absence of bacterial infection as
can be diagnosed by pre-operative synovial fluid cultures and post operative tissue
culture. The destruction of the bone during aseptic osteolysis is due to chronic bone
reabsorption by osteoclasts until fixation of the implant with the bone is lost [4]. Once
thought to be a biological response to wear particulate or a particulate disease [5], it has
been shown that this is too simplistic an explanation as there is a wide variety of implant
material used, yet it has been shown that wear particles do play an important role [6]. The
dominant theory today is that wear particles stimulate cellular responses which initiate
osteolysis through chemical signaling [7]. The wear particles most often associated with
the disease are titanium and polyethylene debris generated from mechanical friction in

the joint [8, 91. Polyethylene particles between the sizes of 0.1 and 1.0 micron have been
shown to be the most reactive [lo].
Osteolysis can be classified as either linear which presents radiographically as a
small generalized linear pattern or aggressive where it presents as large erosive patterns.
Osteolysis has been characterized in knee and hip arthroplasty as a cause for revision
surgery.
Osteolysis is characterized by the forniation of the interfacial membrane (IFM)
around the bone cement interface. This membrane has histological and histochemical
characteristics of a synovial- like lining. The synovial-like cells are oriented adjacent to
the cement layer, while a deeper layer of macrophages forms in closer proximity to the
bone face. T cells are for the most part absent or comparatively few in numbers [ l 11.
There is no significant difference between the IFM of cementless and cemented joints.
The cementlessjoints show more fibroblastic connective tissue though these observations
are not significant. The IFM does stain strongly for IL-1 and TNF-alpha in membranes
from cementless and cemented. The cell participants of the disease include macrophages,
osteoblasts, fibroblasts, and osteoclasts. However, as was shown by Jiranek et al.,
macrophages and fibroblasts were the dominant cell types and less than 10% of the cells
were T lymphocytes [12]. The relative absence of lymphocytes and the variation in
material used in arthroplasty give evidence to the fact that osteolysis is not a lymphocyte
driven immune response against any component of the prosthesis. Rather osteolysis is a
more general disease involving inflammation and changes in cell signaling. The presence
of RANKL has been detected in the interfacial membrane in many recent studies and may
lead to a better explanation of what cells are mediating aseptic osteolysis [13].

RANKLIRANKI OPG signaling pathway
The ligand of Receptor activator of NF-KB which is more commonly known as
RANK Ligand plays a significant role in aseptic osteolysis. RANKL is a 3 17 amino-acid
long protein that is a member of the TNFITNF receptor super family. The primary
function of RANKL is the stimulation of osteoclastic differentiation from osteoclastic
precursors. Additionally RANKL will activate osteoclasts and provide an anti-apoptotic
signal to mature osteoclasts [14]. The primary target of RANKL is the receptor RANK on
pre-osteoclastic cells. The interaction of RANKL and RANK will stimulate the
expression of genes required for osteoclastic differentiation [15]. The role of RANKL
and NF-KB in the formation of osteoclasts has been demonstrated through murine models
and pharmacological blockade. Childs et al. showed that in a mouse model with an
antibody block of RANK-RANKL signaling there was a loss of wear debris-induced
osteolysis [16]. Additionally, Kong et al. demonstrated that RANKL knock-out mice
showed severe ostepetrosis and a systemic depletion of osteoclasts [17]. Two years later
in 2004 Clclhisy showed that a pharmacological blockade of NF-KB signaling inhibits
particle stimulated osteolysis [18]. Recently, Sabokar et al. showed that when RANKL
and sufficient m-CSF were added to a culture of periprosthetic membrane derived
macrophages that formation of osteoclasts would result. Additionally Sabokbar showed
that this formation of osteoclasts could be inhibited by osteoprotegrin (OPG) when it was
added to the culture [19]. RANKL has been shown to have a membrane bound form as
described above but also a soluble form. The soluble form of RANKL is produced by the
interaction of membrane bound RANKL and TNF converting enzyme (TACE). TACE
acts like scissors and clips RANKL from the membrane where it is being expressed and

releases it into extra-cellular environment. The soluble form of RANKL is still capable of
binding to RANK and mediating its effects [20]. RANKL is typically produced by
osteoblasts and stromal cells in response to parathyroid hormone and other hormonal and
inflammatory mediators [2 11. However recently it has been shown that membrane
derived fibroblasts are capable of producing RANKL and supporting osteoclastogenesis
when properly stimulated. The presence of RANKL producing fibroblasts has been
linked to stimulation with titanium wear particles as was shown by Wei et al. [22].
Additionally, human osteoblasts have been shown to produce RANKL in response to
polyethylene particles [9]. Titanium and polyethylene represent two of the major
materials used in the production of joint implants.
The receptor of RANKL is RANK which stands for receptor activator of NF-KB.
RANK mediates the pro-osteoclastic differentiation signal to pre-osteoclastic cells.
RANK is a member of the TNF receptor family and it mediates its effects when bound by
RANKL which is also called TRANCE, ODF, or OPGL. RANK is a transmembrane
protein that is 616 amino acids long. RANK is typically expressed on cells of myeloid
lineage thus including monocytes, macrophages, dendritic cells, and lymphocytes. Many
of these types of cells are also pre-osteoclastic cells and have the ability to differentiate
into osteoclasts when given the proper signaling [14]. In the case of osteoclastic
differentiation the proper signaling involves cell to cell interaction of RANKL expressing
cells with RANK expressing cells. RANK signaling in pre-osteoclastic cells involves the
binding of the cytoplasmic RANK domains with TRAF-2,5 and 6 [23]. Osteoclast
precursor cells demonstrate an interaction of TRAF-6 and cytoplasmic RANK domains
when extracellular RANK domains are bound by RANKL [15]. The effect of TRAF-6 in

the RANK signaling pathway can be fbrther demonstrated by the fact that TRAF-6
deficient mice show symptoms of osteopetrosis and have improperly functioning mature
osteoclasts [24].
The last part of the RANKLIRANK signaling pathway is osteoprotegrin (OPG).
OPG is produced by mesenchymal cells that are also associated with RANKL production
however OPG lacks a transmembrane region and thus is secreted from the cells
producing it into the extracellular fluid [25]. OPG like RANK has several names; it is
also known as osteoclast inhibition factor (OCIF) or TNF receptor like molecule 1 (TR1).
The function of OPG is to act as a soluble decoy receptor of RANKL [26]. To this effect,
the binding or OPG to RANKL effectively blocks RANKL's ability to bind RANK and
cause osteoclastic differentiation. The name osteoprotegrin translates to "protector of
bone". OPG is a protein that is synthesized in the cell as a protein of 40 1 amino acids but
is later cleaved into a 380 amino acid molecule when it is secreted [14]. OPG is classified
as a heparin binding glycoprotein with seven structural domains that is part of the TNF
receptor superfamily however unlike many other members of that family as stated above
OPG is not membrane bound, it is secreted by stromal cells and osteoblasts which are the
same cells that produce RANKL [27]. The importance of OPG inhibition of RANKL
signaling has been demonstrated in that OPG knockout mice showed severe osteoporosis
which was ultimately the result of increased bone reabsorption [28].
The role of m-CSF has been demonstrated by Takami et al. They showed that in order for
RANWRANKL interaction to cause osteoclastogenesisthere must be sufficient m-CSF
present. However, m-CSF was shown not to be necessary to activate mature osteoclasts
to begin reabsorbing bone as RANKL is [29]. Thus, it can be concluded that while m-

CSF is a necessary co-factor of RANKIRANKL mediated osteoclastogenesis it is not
necessary for RANKLIRANK mediated activation of mature osteoclasts or the inhibition
of osteoclasts apoptosis.
TNF-a, IL-1p and IL-6
The wear particulate generated through mechanical grinding of the bone against
the prosthesis followingjoint arthroplasty leads to inflammation in the joint. This
inflammation is mediated by pro-inflammatory cytokines. Work by Jiranek et al. (1993)
determined that though there are many different cytokines in the IFM the most prevalent
ones based on irnmunostaining were IL- and TNF-alpha [12]. IL-6 has also been
associated with the interfacial membrane and seems to be produced by fibroblasts in the
membrane [30,3 11.
TNF-alpha is a homotrimer of 157 amino-acid subunits first cloned in 1984. TNFalpha is primarily produced by activated macrophages and mediates many proinflammatory effects. TNF-alpha signals through the surface receptors TNF-R1 and TNFR2. Of these two receptors it has been determined that TNF-R1 mediates the majority of

TNF-alpha's biological effects. TNF-alpha's signaling pathway eventually results in the
activation of the transcription factor NF-KB. To this effect, TNF-a signals in the same
method as RANK and explains why they are in the same family of receptors. NF-KB
activation occurs through the phosphorylation-dependentubiquitination and degradation
of IuB proteins. NF-KB is usually bound by this inhibitor protein however once they have
been degraded NF-KB is free to move into the nucleus from the cytoplasm and cause
transcriptional change [32].

Interleukin 1 is one of the most important pro-inflammatory cytokines and there
are three variants of it found in the body. IL- 1a, IL- 1P, and IL- 1Ra are the three members
of the IL-1 gene family. IL-la and beta are both synthesized as precursors without leader
sequences. Following translation, they have a molecular weight of 3 1,000, however
following processing by cellular proteases into their mature form they drop to a
molecular weight of 17,000. IL-Ra is conversely translated with a signal peptide and is
excreted from the cells prior to being modified by proteases. Similar to TNF-a, IL-1 P
also leads to the activation of the inhibitory kappa B complex and the destruction of IKB
allowing NF-KB to be activated and enter the nucleus. Of all the variants of IL- 1, it is IL-

1p that appears to play the most significant role in osteolysis [33]. Macrophages isolated
and cultured from the interfacial membrane are capable of producing large amounts of
IL-1 P in response to wear particles typically found in the IFM [33]. Additionally, it has
been seen that in patients with aseptic loosening of hip replacements there is a serum
elevation of IL- 1P[34].
Moreschini et al., hypothesized that these two inflammatory cytokines of IL-1P
and TNF-a play a direct role in the formation of aseptic osteolysis through the
stimulation of RANKL expression and thus increase osteoclastogenesis [35]. The
question of how the two cytokines up-regulate RANKL is still unclear. Whereas Ma et
al., demonstrated that IL- 1P is able to increase osteoclastogenesis in a murine model
when there are permissive levels of RANKL. This process seems to be independent of
TNF-a [36]. Additionally a more recent study has shown that TNF-induced RANKL upregulation is actually mediated by IL-1P. To this effect, TNF-a is unable to stimulate
osteoclastogenesis on its own [37]. It was also demonstrated independently by two

groups that TNF-a alone cannot activate mature osteoclasts to begin reabsorbing bone
[38,39]. However, these two studies have been challenged in recent years as a study by
Fuller et al., showed that TNF-a does potentially activate mature osteoclasts through a
RANKL independent manner, but that it is synergistic with RANKL [40]. Furthermore,
Sabokbar et al. demonstrated that TNF-alpha is sufficient to induce osteoclasts
differentiation from arthroplasty macrophages provided that there is sufficient m-CSF
present. The study by Sabokbar et al. also showed that TNF-a and IL-1a were capable of
stimulating bone reabsorption independently but that in culture they could act
synergistically. Thus, there appears to be a RANKL/RANK independent system for
stimulating osteoclastogenesisand osteoclasts activation. This would be likely to operate
in a system such as the interfacial membrane where there is a high level of cytokine
production due to the wear particulate being generated [411. Whether TNF-a and IL- 1 are
able to stimulate osteoclastogenesis independent of RANKL, or whether they simply upregulate RANKL, is still unclear.
IL-6 has been shown to be present in the membrane in high levels particularly in
areas of dense fibroblasts as opposed to IL-1 and TNF-a which are more localized to the
areas occupied by high numbers of macrophages [42]. It appears based on current
research that IL-6 is produced by fibroblasts in the membrane in response to IL-1 and
TNF-a [311. IL-6 is produced from monocytes and T-cells in response to trauma in the
body. IL-6 signals through the JAK-STAT pathway and is expressed when mechanical
trauma or stress is placed on the body. The grinding of the prosthesis on the bone could
thus be a stimulus for IL-6 production in aseptic osteolysis.

Recent evidence from the Cleveland clinic has suggested that bacterial endotoxin
found on the prosthesis and on wear particulate can accumulate in the IFM. This
accumulation of endotoxin is a stimulus for inflammatory cytokines to be released by
macrophages and thus endotoxin would contribute to the over all environment of
inflammation in the IFM [43].
Cell Composition of the IFM

Classical characterization of the IFM indicates it is coniposed primarily of
fibroblasts and macrophages 1121. Macrophages are phagocytes of the innate immune
system that are major producers of inflammatory cytokines and mediators of
inflammation. Macrophages in the interfacial membrane have been shown to actively
engulf wear particulate from the prosthesis which in turn causes them to release more
cytokines [5]. Macrophages play a dual role in osteolysis in that they are the major cell
type host defense responding to wear particles via ingestion and the production of
cytokines TNF-a and IL- 1P, however they also are the precursors for osteoclasts
responsible for ensuing bone reabsorption [lo]. The b c t i o n of osteoclasts is the
reabsorption of bone through enzymes that break down the collagen matrix and remove
phosphate and calcium ions into the blood. An over abundance of osteoclastic bone
reabsorption is the root problem in osteolysis.
Prior research in this laboratory

RANKL is a potent activator of bone reabsorption. The focus of osteolysis
research for the past 4 years in this lab has been RANKL present in the membrane and
what its source might be. This began in 2002 with a study by Beckman et al. where
characterization of the IFM as having two distinct layers based on cellular composition.

The layer of the IFM closest to the bone was composed of significantly greater @<0.001)
numbers of macrophages while the IFM layer closest to the prosthesis was composed of
significantly greater @<0.00 1) numbers of fibroblasts (Table 1). The study also
demonstrated that the two layers of IFM differ based on cytokines present. TNF-a gene
expression was detected uniformly throughout the IFM, whether close to bone or close to
the implant. In contrast, IL-1P gene expression was much more significantly detected in
the IFM adjacent to the bone, whereas, IL-6 gene expression levels were found to be
significantly higher in the IFM near the prosthesis than near to bone [44]. During this
study, RANKL was detected in RNA isolated fiom the interfacial membrane. RNA was
isolated fiom the IFM in areas against lytic bone reabsorption versus from control nonlytic areas (Figure 1). This approach demonstrated that IFM tissue against areas of lytic
bone reabsorption are significantly greater in the concentration of RANKL than in those
areas of IFM that were forming against intact bone [45]. This evidence suggested that
RANKL was present in the IFM and played a role in bone reabsorption. This was
confirmed in a study by Li et al. (2006b) in which fibroblasts isolated from the IFM were
positive for RANKL and negative for CD14 [46]. Observations of the IFM using
RANKL fluorescent antibodies and 400x microscopy revealed a large RANKL positive
cell (Figure 2). Upon fbrther investigation of this cell, it was also noted that it stained
negative for multiple macrophage markers and positive for fibroblast markers and
appeared multi-nuclear[47]. The presence of a multi-nuclear fibroblast suggests several
different mechanisms of cell fision, one of those being viral involvement.

Table 1: Characteristics of different layers of interfacial membrane
Table 1A: Shows the observed cellular composition of IFM as determined through five
field counts at 400x of tissue sections. (p <0.001)
Table 1B: Shows the cytokine profiles of the two different layers of the IFM. (p<0.001)
(tables courtesy of Mengnai Li)
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Figure 1: RANKL concentration in the IFM
Figure 1 shows the greatly elevated RANKL levels at the site directly associated with a
lytic lesion as opposed to control IFM harvested from sites away from the lesion in the
same respective patient (p<0.001)
(figure courtesy of Mengnai Li)
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Figure 2: First observation of a RANKL positive giant cell in IFM
Figure 2A: Panel A shows an image (400x) of the nuclei (blue) associated with this
image. Whereas, Panel B depicts a composite picture of antibody staining for 5B5 (red)
and RANKL (green).
Figure 2B: Panel A shows an image (400x) of the nuclei (blue) associated with this
image. Panel B shows the composite picture of RANKL (green) and BerMac3 (red)
antibodies stains.
(images courtesy of Sam Rarnage)

Viral Mediated Cell Ii'usion
Cells hsed by virus are generally considered harmless and nonfunctional,
however recent evidence suggests that these fused cells are capable of proliferation and
survival and that their existence can mediate negative consequences on the body [48].
There are several viruses implicated in cell fusion of which a large group is the herpes
family of viruses.
Cytomegalovirus is a member of the herpes family of viruses and shares the
characteristic of most herpes like viruses in that once infected with CMV a patient will
carry the virus for life and shed it intermittently [49]. CMV has the largest genetic
content of the human herpes viruses with a DNA genome of 240 kbp. It is estimated that
close to 90% of the population is infected with CMV however the symptoms are mild
enough to escape diagnosis upon initial infection. It is also estimated that at any given
time about 10% of the population is shedding CMV. It appears that the primary trigger
for CMV to be brought out of latency is irnrnunosuppression and for this reason it is a
major cause of death in transplant recipients and AIDS patients. Infection can be detected
histologically through observation of foci of swollen retractile cells with cytoplasmic
granules. These cells are multi-nucleated and have smooth round acidophilic cytoplasmic
masses, however a hallmark of infected cells are pathognomonic large arnphophilic
"skein like" nuclear inclusion bodies. CMV infected cells are typically swollen and are
multi-nucleated in addition to having multiple perinuclear cytoplasmic inclusions and
intranuclear inclusions. A study by Garnett demonstrates that CMV infection of
fibroblasts causes the formation of giant multi-nucleated cells [50]. The absence of
bacterial infection in aseptic osteolysis does not rule out the possibility of viral

involvement since assays to determine bacterial infection could easily miss viral
infection.

Focus of current project
The major focus of the following research will be the characterization of the

RANKL positive giant cell, which will be referred to as (RPGC). This RPGC was stained
with an extensive battery of antibodies in order to clarify its lineage, role in the IFM
tissue, and the possible role of CMV in its fusion. Furthermore all studies presented will
involve an increase in imaging used on this cell from 400x to 630x. The increase in
magnification will attempt to determine if this RPGC is in fact a multi-nucleated cell or a
dense group of cells collectively expressing RANKL. We hypothesize that the RPGC in
the IFM tissue is a multi-nucleated fibroblast-like cell characterized by intense RANKL
expression and formed through fusion of fibroblasts that were infected by CMV.

CHAPTER 2
IMMUNOFLUORESCENT ANALYSIS OF THE RANKL PRODUCING GIANT
CELL FOUND IN THE INTERFACIAL MEMBRANE
(A CASE STUDY)
ABSTRACT
This case study was to attempt to characterize the RANKL expressing giant cell
or cluster of cells seen in all interfacial membranes examined by this lab. This case study
was performed on tissue taken from a 77 year old female undergoing revision hip surgery
due to aseptic osteolysis. This patient displayed a rapid progression of osteolysis and a
high level of the RANKL expressing cells. Tissue removed from this patient was frozen
and cut into 12 micron sections. The sections were stained with antibodies to fibroblast
cells (D7-fib), antibodies to macrophages (Ber-Mac), and antibodies to inflammatory
cytokines (TNF-a, IL-1P, and IL-6). In addition antibodies to cytomegalovirus were used
in the cells characterization. For the purposes of this study all samples were incubated
with RANKL antibody and its presence was used in identification of the cell to which the
staining of the other antibodies was characterized.
The results showed that the RPGC stained negative with the Ber-Mac antimacrophages antibody. The RPGC did however stain positive with the D7-fib antifibroblast antibody and all three inflammatory cytokines. The RPGC also demonstrated
positive staining for the CMV antibody.
This study first documents the existence of a multi-nucleated cell in the interfacial
membrane that expresses high concentrations of RANKL. Our data suggest that this
RPGC is not of myeloid lineage, is positive for the presence of TNF-a, IL-P, IL-6 and is
most likely fibroblast-like. In addition this RPGC is positive for CMV antigen.

INTRODUCTION
The formation of the interfacial membrane is a characteristic of periprosthetic
osteolysis leading to total joint failure. This membrane forms between the prosthesis and
the bone and has been referred to as synovial-like due to the thin layer of polygonal cells
(1-2 cells thick) that forms abutting the cement or prosthesis[l 1,511. However away
from the prosthesis this membrane becomes very thick and is composed primarily of
fibroblasts and macrophages. In this sense, interfacial membrane (IFM) is perhaps a
misnomer and should be referred to as a tissue, however, in this document the tissue and
membrane will be labeled IFM or IFM tissue. The IFM has been uniquely associated with
osteolysis in that when revisions of joint arthroplasty are done for reasons of meclianical
failure or sepsis the IFM is not observed. The composition of the IFM tissue was
determined in 1993 by Jiranek et al. as being primarily composed of fibroblasts and
macrophages with relative low numbers of T cells and osteoblasts [12]. The
RANKL/RANK/OPG system has been implicated in the development of osteolysis with
some question given to the source of the RANKL. There have been recent reports
demonstrating that RANKL is expressed in fibroblasts isolated from the IFM and that it is
capable of inducing osteoclastogenesisin vitro that could mediate bone reabsorption [52,
531. In previous studies using confocal microscopy and irnrnunofluoresence in this lab, a
large multi-nucleated cell or cluster of cells that stains very intensely with RANKL has
been observed.
The purpose of this study was to characterize this cell and determine the cell type
it might be using antibody staining and high power confocal microscopy. Although all
IFM tissue samples observed have demonstrated examples of this multi-nuclear cell there

are very few of them per tissue section. One patient however showed a remarkably high
amount of these cells in her tissue as is demonstrated in Figure 3. The relative
abundance of these multi-nuclear cells in this periprosthetic tissue made the patient a
great case study with which to M h e r characterize this cell. To characterize the lineage of
this cell, many serial sections were made of the tissue and stained with a panel of
antibodies to determine the classification of this cell that so highly expresses RANKL.
The antibodies used were specific for cells of mesenchymal or myeloid origin. This
direction was based on the composition of the IFM as determined through prior work
documenting that fibroblasts and macrophages were the two major cell types present in
the IFM [42]. Additionally, the presence of inflammatory cytokines in the interfacial
membrane has been well characterized with particularly high levels of TNF-a, IL- 1P and
IL-6. Therefore, emphasis was also on relating the staining pattern of RANKL with the
individual staining patterns of these three cytokines.
The patient chosen for this study showed a high level of the cell in question when
observed using a 40x objective (figure 3). However for the purposes of cell
characterization the power of the scope was increased to a 63x objective to allow more
detail to be seen. The tissue used for this study was obtained from a 77 year old female
undergoing revision of the acetabular component of a right hip prosthesis on 11/7/05. The
patient received her primary hip arthroplasty on 211 1/00 at age 7 1. Thus the patient was
able to tolerate the implant for a little over 5 years. However the patient was required to
have a femoral component revision on 8/6/2000 due to fracture and sepsis and not the
result of osteolysis. The patient's serial radiographs between October 2000 and May 2003
showed no signs of osteolysis and it was noted by the surgeon at the time of her May

2003 clinic visit that the patient exhibited "no lucency and good bone stock". This was
followed by the same surgeon's preoperative notes in 2005 as stating that "the patient's
acetabulum is grossly loosened and sitting at essentially 90 degrees of abduction, the
patient has a very large superolateral defect that would be graded as a type II". The
difference of approximately 2.5 years between these two radiographic reports suggests an
extremely rapid form of osteolysis around the acetabular component. This case is of
particular interest due to the fact that osteolysis was clearly observed as not being a factor
in 2003 and less than 3 years later had led to complete loss of fixation of the acetabular
component. The correlation between the patient's rapid loss of fixation coupled with a
high number of these RANKL expressing cells is worth noting.

MATERIALS AND METHODS
Tissue preparation
Tissue was obtained from one 77 year old female undergoing revision hip
surgery. The interfacial membrane was kept at 4O C following removal from the patient;
the tissue was then embedded in OCT compound (Tissue-Tek) and frozen at -20°C until
it was sectioned. The sections were made at 12 microns on a cryostat and melted on to
superfrost microscope slides (Fisher Scientific). Frozen sections were kept at -20°C until
stained.
Antibody Staining
Frozen sections were fixed using ice cold 100% methanol for 60 seconds and then
washed with PBS. The slides were blocked with a 3% goat serum PBS mixture and
washed in .01% triton for ten minutes. The triton wash was to decrease non-specific
binding. Antibodies were prepared in PBS dilutions with 1% goat serum. Primary
antibodies were diluted 1:50 and secondary antibodies were diluted 1:200. Antibodies
were incubated for 1 hour at room temperature and following each incubation the
sections were washed 5 times with PBS and once with a .01% triton solution to minimize
non-specific binding. All sections were stained with Hoechst 34580 stain diluted 1:200 in
PBS. Table 2 summarizes all information on antibodies used in this study.
Analysis of Immunolabeling
Slides were observed using a Carl Zeiss LSM 5 10 Meta confocal imaging
microscope. The lasers used for analysis were the 405nm diode laser, a 488nm Argon
laser, and a 54311x11 Helium Neon laser. The first image of the tissue to determine
abundance or giant cells was taken using a 40x oil immersion objective. Individual cells

were observed using a 63x oil immersion objective. In each case the characteristic intense
RANKL staining was used to target cells for analysis. The sections were analyzed using
FITC fluorescence to locate the characteristic intense RANKL staining. Once located the
examples were checked with light microscopy to ensure that a distinct cell was present.
In all examples a Hoechst nuclear stain was used to determine if examples were multinucleated or not as this was a characteristic of previously examined cells.

Table 2: Antibodies used in case study
Table 1 summarizes the information on the antibodies used in this study including their
name, host animal, fluorescent secondary and supplier.

antibody

primary host
animal

CMV monoclonal

mouse

RANKL polyclonal

goat

RANKL monoclonal

mouse

Mac3 monoclonal
TNF-alpha
monoclonal

mouse
mouse

IL-I monoclonal

mouse

IL-6 monoclonal

mouse

D7-fib monoclonal

mouse

Secondary antibody
543 chicken antimouse
488 donkey anti-goat
543 chicken antimouse
543 chicken antimouse
543 chicken antimouse
543 chicken antimouse
543 chicken antimouse
543 chicken antimouse

Supplier
Chemicon International
Santa Cruz
Biotechnology
R & D systems
Dako Corporation
R & D systems
R & D systems
R & D systems
Gene Tex

RESULTS
DIC imaging of the multi-nuclear giant cell
The use of the 63x objective allowed for increased magnification and greater
resolution. This increase in magnification led to the ability to visualize the morphology of
this giant cell under light microscopy. The light images were taken using a Differential
Interference Contrast (DIC) filter on the confocal microscope where only the halogen
lamp was ignited. The light images revealed a definitive structure in the interfacial
membrane that corresponded to the RANKL staining. The DIC imaging gave validity to
the RANKL image that the antibody was specifically binding to a structure as seen in

figure 4. This characteristic structure was then used to evaluate all further images and
confirm that in each case a defined cellular shape was observed in addition to the
fluorescence. The multiple Hoechst stains inside the cell indicating multiple nuclei are a
characteristic of this cell (figure 4). All examples observed were multi-nucleated.

Controls
In order to control for non-specific binding, several control slides were made and
analyzed. The first set of controls consisted of secondary antibody controls. In that every
primary antibody used in this study was not coupled to a fluorescent antibody it was
necessary to use secondary fluorescent antibodies raised against the host species of the
primary antibody. For this set of experiments the RANKL antibody used in all sections to
target the giant cells was a polyclonal antibody raised in goats against humans. An antigoat secondary antibody that was designed to excite when hit with a 488nm laser was
used as its secondary. All other primary antibodies used in this study and which were
evaluated for their co-localization with RANKL, were raised in mice against humans.

These antibodies were detected by an anti-mouse secondary-conjugated to a fluor group
designed to excite when hit with a 543nrn laser. When evaluated alone these secondary
antibodies showed limited or no fluorescence indicating that they did not specifically
bind to the tissue. Additionally, since polyclonal RANKL antibody was used in every
section it was necessary to confirm that it was binding specifically to RANKL. To this
effect, a section was stained with both RANKL polyclonal antibody and RANKL
monoclonal antibody. The two antibodies bound to the same cell indicating that the
RANKL polyclonal antibody was specifically binding to RANKL and validating the

RANKL binding in other tissues.
Fibroblast and macrophage specific antibodies

The purpose of this study was to characterize this multi-nucleated cell. Based on
previous research, it has been demonstrated that the interfacial membrane is composed
primarily of fibroblasts and macrophages [42]. It was thus necessary to determine if this
multi-nucleated cell was either of macrophage or fibroblast origin. To examine this, the
tissue section was incubated with D7-fib a very specific monoclonal antibody to antigen
on fibroblasts and epithelial cells. The staining of D7 was very specific for the RANKL
producing cell and demonstrated considerable intensity in staining.
Mac3 is a very specific marker for cells of myeloid origin. The human form of it
is also known as Ber-Mac3 and has been used in many studies involving the IFM to
identify macrophages[54]. The staining with Ber-Mac3 demonstrated no co-localization
with the RANKL producing cell. However, there was an interesting result in that there
was some intense Mac3 staining of cells peripheral to the RANKL producing cell.

Inflammatory cytokine specific antibodies

The production of inflammatory cytokines in the interfacial membrane has been
demonstrated and the IFM has been characterized as a zone of intense inflammation. The
TNF-a antibody stained the RPGC well and in roughly the same pattern as the RANKL
antibody. The TNF-a staining approximates the staining seen with the RANKL staining
as seen in figure 5A. In contrast to the TNF-a staining, IL- 1P shows a much different
staining pattern. This staining of RANKL in association with IL-1P shows that IL-I P is
an intense signal in the middle of the RPGC approximately with several nuclei in the
interior of the cell (figure 5B). The staining pattern of RANKL with IL-6 showed that
while IL-6 is present in and around the RPGC, the IL-6 signal was low in intensity as
compared to the other inflammatory cytokines. Though diminished, this IL-6 signal did
appear on the outer edge of and within the RPGC indicating IL-6 was associated with the
RPGC (figure 5C). All the inflammatory cytokines detected were bound with
monoclonal antibodies and thus it would seem likely that all three inflammatory
cytokines assayed are present in or on the RPGC indicating either the cell is bound by
them or the cell is producing them in levels according to the intensity of the stain.
Cytomegalovirus antibody

The staining patterns seen on the RPGC indicate that it is of fibroblast origin and
therefore raises the question as to how a fibroblast might form. The formation of a multinucleated fibroblast indicates cellular fusion of multiple mono-nucleated cells. There are
several viruses of the herpes family that have been implicated in fibroblast fusion one of
the most common of them being cytomegalovirus (CMV) [50].We thus stained the

W G C with a monoclonal antibody directed against a CMV protein. The CMV antibody
did stain the RANKL producing cell though not in the same pattern as RANKL. The
staining of CMV seems to associate with the Hoechst stain indicating that the epitope of
the CMV antibody is in or in close proximity to the cell's nuclei as seen in figure 6. The
staining was intense and approximated the shape of the cell as determined through DIC
imaging. These data indicate that the RPGC is positive for CMV detection.

Figure 3: Presence of multiple RANKL positive giant cells in the
interfacial membrane sample obtained from patient BJ020.
The figure shows several of these giant multi-nucleated RANKL positive cells in one
field. Though these are present in all IFM samples so far observed they are usually fairly
rare with this tissue being an exception. RANKL is denoted by the green color and the
nuclei are denoted by the blue color. This image was taken at 400x magnification.

Figure 4: Observation of the RPGC using light microscopy. Panel a, shows
the RANKL giant cell using the DIC filter and halogen lamp on the confocal microscope.
Panel b, shows the same cell with the 405nm and 488nm laser activated to show
fluorescence of RANKL (green) secondary and Hoechst nuclear stain (blue). Image taken
at 630x.

Figure 5: Controls of Case study.
Figure 5A. shows the secondary antibody controls for this experiment. Panel a,
shows the anti-goat 488nm alexa fluor antibody. Panel b, shows the staining of antimouse 543nn1 alexa fluor antibody.
Figure 5B. shows the staining of the RANKL polyclonal and RANKL monoclonal
antibodies. Panel a, shows the RANKL polyclonal antibody with anti-goat secondary
(green). Panel b, shows the RANKL monoclonal antibody with anti-mouse secondary
antibody (red). Panel c, shows a composite picture of both antibody stains combined with
a Hoechst nuclear stain (blue). Image taken at 630x.

Figure 6: Staining of macrophage and fibroblast specific markers.
Figure 6A shows RANKL and D7-fib staining. Panel a, shows RANKL antibody
staining with anti-goat secondary (green). Panel b, shows D7-fib antibody staining with
anti-mouse secondary (red). Panel c, shows a composite picture of the two antibody
stains with Hoechst nuclear stain (blue). Image taken at 630x.
Figure 6B shows RANKL and Mac3 staining. Panel a, shows RANKL antibody
staining with anti-goat secondary (green). Panel b, shows Ber-Mac3 antibody staining
with anti-mouse secondary (red). Panel c, shows a composite of the two antibody stains
with Hoechst nuclear stain (blue). Image taken at 630x.

Figure 7: Staining of the RPGC with antibodies of inflammatory
cytokines typically seen in the IFM.
Figure 7A shows the staining of the RANKL expressing cell with TNF-alpha
antibody. Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the TNF-alpha antibody staining with anti-mouse secondary
(red). Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear
stain (blue). Image taken at 630x.
Figure 7B shows the staining of the RANKL expressing cell with IL-1. Panel a, shows
RANKL antibody staining with anti-goat secondary (green). Panel b, shows IL- 1
antibody staining with anti-mouse secondary (red). Panel c, shows a composite picture of
the two antibody stains with together with Hoechst nuclear stain (blue). Image taken at
630x.
Figure 7C shows the staining of the RANKL expressing cell with IL-6. Panel a, shows
RANKL antibody staining with anti-goat secondary (green). Panel b, shows IL-6
antibody staining with anti-mouse secondary (red). Panel c, shows a composite picture of
the two antibody stains with together with Hoechst nuclear stain (blue). Image taken at
630x.

Figure 8: Staining of the RPGC with an antibody for cytomegalovirus.
Panel A, shows RANKL antibody staining with anti-goat secondary (green). Panel B,
shows CMV monoclonal antibody staining with anti-mouse secondary (red). Panel C,
shows a composite picture of the two antibody stains with together with Hoechst nuclear
stain (blue). Image taken at 630x.

DISCUSSION
The formation of the interfacial membrane and its associated granuloma tissue is
the sinequanon of the disease of aseptic osteolysis. We have examined this membrane to
determine the cell source of the RANKL and in so doing we observed large multi-nuclear
cells that express very concentrated levels of RANKL. RANKL is a potent membrane
bound pro-bone reabsorbing cytokine. In this study we used various antibodies to cellular
antigens and inflammatory cytokines in order to classify this RANKL producing cell. The
study was performed on a 77 year old female's tissue that had an abundance of these cells
present. The main antibody used for RANKL was a goat anti-human polyclonal specific
to the extra-cellular domain of membrane intact RANKL.
The first antibody used was D7-fib. The purpose of this was to determine if the

RANKL producing cell co-localized with D7-fib and thus was of fibroblast origin. The
D7-Fib antibody recognizes a 112 kD molecule expressed on the cell surface of human
fibroblasts and epithelial cells. The antibody does have the ability to bind to peripheral
blood myeloid cells and in some cases smooth muscle. However in tissue it primarily
targets fibroblast cells and epithelial cells. The antibody used in this study was a
monoclonal antibody for D7 raised in mice and obtained from GeneTex. The staining of
D7 with the RANKL closely approximated the same cellular pattern that the RANKL did.
Because D7- fib antibody is specific to fibroblasts and the intense staining seen with D7fib was so well co-localized with the RANKL antibody staining, these data indicate that
the RANKL producing cell is fibroblast-like.
The formation of giant cells is not uncommon in the body and particularly with
procedures involving prostheses implanted into the body. This has not only been

demonstrated with total joint arthroplasty [5,55], but also with breast augmentation and
the saline implants typically used in that procedure [56]. However foreign body giant
cells (FBGC) are typically of myeloid origin thus it was necessary to stain the RANKL
positive giant cell (RPGC) of this study with a myeloid markers in order to determine if
this RPGC was of myeloid origin or not.
The antibody Ber-Mac3 is the human equivalent of murine Mac3 in that both are
anti-CD163. CD 163 is a member of the scavenger receptor super-family. In humans,
CD163 mediates the uptake of hemoglobin-haptoglobin complexes. It is expressed by
monocytes and macrophages. The Ber-Mac3 antibody was obtained from the DAKO
Corporation and was raised as a monoclonal antibody in mice. The staining of the BerMac3 antibody did not localize with the RANKL cell and showed no intensity on the cell
denoted by the RANKL stain. However the Ber-Mac3 antibody did bind to cells
surrounding the RANKL cell and showed some intensity there. This staining pattern is
consistent with the current theory that pre-osteoclastic cells are myeloid in origin and
must directly interact with RANKL producing cells in order to become mature
osteoclasts. In previous co-localization from our laboratory the antibodies for RANKL
receptor (RANK) and Ber-Mac3 have shown strong super-imposable co-localizing
staining patterns (data not shown). This observation is consistent with the theory that BerMac3 and RANK double positive cells surround a RANKL giant cell possibly interact
with RANKL and receive pro-osteoclastic signals. This data is not by itself conclusive
enough to confirm RANKL-mediated osteoclastogenesis, however, it provides sufficient
evidence to suggest IFM macrophages are devoid of RANKL expression on their cell

surface, broadly supports our proposal that RPGCs of the IFM are not derived from the
monocyte lineage.
Several reports by our group and by others document the expression of numerous
inflammatory cytokines capable of regulating bone reabsorptive process in osteolysis
namely, IL- 1j3, IL-6 and TNF-a [12,4 1,42,57]. The production of inflammatory
cytokines by this RPGC was examined. TNF-a is one of the most common cytokines in
the body and is produced by multiple cells in the body including fibroblasts and
macrophages. Fibroblasts produce TNF-a in response to tissue damage and inflammation
such as occurs in rheumatoid arthritis [58]. Macrophages, on the other hand, can respond
to a plethora of foreign and natural factors by release of cytokine mediators. Particulate
stemming from the metal, plastic or cement of prosthetic devices, as well as cell wall
material of bacteria like LPS can activate IFM tissue macrophages to begin secreting
cytokines. It is clear from a number of well controlled studies in the field of arthroplasty
that macrophage activation and cytokine release is an important determinant of osteolysis
[12,33,55]. TNF-a showed a staining pattern that was consistent with the general shape
of the RPGC, as if it was present on its surface. These data suggests that either the
RPGCs produce TNF-a or it has abundant soluble TNF-a bound to its surface.
IL-1P is also a very common inflammatory cytokine and is very common to the
interfacial membrane[l2]. Interestingly, IL-10 staining did not approximate the shape of
the cell but was very intense in the cell interior. This observation could indicate this cell
is actively translating IL- 1P in its cytoplasm but that it is secreting low levels of it or that
the secreted IL- I P was washed away. IL- I P like TNF-a can be produced by fibroblasts in
response to inflammation.

In contrast, RPGC stained the least intensely for IL-6. The staining pattern for IL-

6 was very weak and did not localize well with the cell indicating this cell was producing
low levels of IL-6 or that very little was bound to it. Prior work by our lab has shown the
majority of IL-6 expression was in regions more highly populated by membrane
fibroblasts than macrophages. This may indicate that the release of IL-6 from RPGC is
highly efficient.
The inflammatory cytokine panel used in the present study indicates that the
RPGC is capable of producing and it likely is actively producing inflammatory cytokines.
Alternatively, the evidence might also suggest that the RPGC binds high levels of the
cytokines. The staining pattern with IL-1P seems to suggest that IL-1P is being produced
in the cell cytoplasm due to the intense staining inside the cell and no where else. The
production of these cytokines is not inconsistent with this cell being of mesenchymal
origin in that mesechymal cells in an environment of inflammation are capable of
producing IL-1P and IL-6 [30,59] Furthermore all three cytokines have been
demonstrated as being produced by fibroblasts in response to particulate and bacteria
[601.
The presence of a multi-nucleated fibroblast is certainly of some concern and
raises the question as to what conditions would cause a multi-nucleated fibroblast to
form. It has been documented that certain viruses of the herpes family can cause hsion of
cells leading them to become multinuclear. One of these viruses in particular is
cytomegalovirus (CMV). Garnett (1979) determined that CMV infection was capable of
causing fibroblasts to fuse and form giant multinucleated cells [50]. We obtained a CMV
monoclonal antibody from Chemicon International. This antibody was raised in mice

causing fibroblasts to fuse and form giant multinucleated cells [50].We obtained a CMV
monoclonal antibody from Chemicon International. This antibody was raised in mice
with reactivity to human E l - 7 2 and E2-86 proteins. El and IE2 are immediate early
proteins that are expressed in the first hour of infection and then over the entire course of
CMV infection. Like most herpes viruses CMV goes through cycles of latency and active
replication and like most other herpes viruses there is a high infection rate in the
population with those infected experiencing repeated outbreaks from then on. The
staining for CMV co-localized with the RANKL in each RPGC examined showing
specificity and intensity of staining. These data document that the RPGCs in this patient
are positive for CMV.
In order to control for false positive autofluoresence, we stained several sections
with secondary antibody only. There was some staining noted and this can be attributed
to the fact that this tissue is very carbohydrate dense and thus very sticky. As the methods
demonstrate the tissues were washed stringently following incubations, however some
non-specific binding was unavoidable. A final control used to validate our comparison
data was use of a RANKL monoclonal antibody. Since RANKL was used in each
staining it was necessary to confirm that the RANKL polyclonal antibody used was
accurately binding RANKL. This RANKL monoclonal did in fact localize with the
polyclonal indicating that both antibodies were adhering to RANKL and the polyclonal
was providing accurate results. This result would validate the RANKL polyclonal binding
pattern and indicate that there is significant RANKL being expressed on the membrane of
this cell.

cellular structure and not a mass of fat or carbohydrate that bound antibody nonspecifically. Using the DIC images as a guide, it was possible to confirm there was a cellbased structure present in the membrane that the antibody bound to specifically. The DIC
images also give insight into the unique morphology of this cell; it does appear that this
cell is not a normal portion of the tissue as the continuity of the tissue is disrupted by the
cell structure. This supports the concept that the RPGC is not a normal structure, but
rather a bizarre anomaly present in the IFM possessing high RANKL expression.
This case study represents the first of it kind to characterize a RPGC in the IFM of
a periprosthetic osteolysis patient. Further studies will be done to M h e r characterize the
nature of this novel giant cell, and to determine if CMV plays a role in its formation.
Presently it is sufficient to say that the RPGC produces a high concentration of RANKL
and is a resident feature of the IFM. Furthermore, based on high powered confocal
images, the RPGC appears to be multinucleated, is positive for fibroblast cell markers

and is negative for markers of myeloid lineage. Based on this, we propose the RPGC is
fibroblast-like cell type. This study identifies an important case history of osteolysis and
an individual with multiple RPGCs present in the IFM. This study made use of greater
resolution and detail of this cell type viewing this cell at 630x magnification as opposed
to previous work by our laboratory that used 400x. Using transmission electron
microscopy we will further try to increase the resolution and detail with which we see
this cell and definitively answer the question of whether it is truly multi-nucleated or not.

CHAPTER 3
RESIDENT FIBROBLAST GIANT CELLS IN THE PERPROSTHETIC
MEMBRANE ARE RANKL POSITIVE AND CO-LOCALIZE WITH CMV AND
TACE
ABSTRACT
The previous work by this laboratory has demonstrated the presence in the IFM of
a RANKL positive giant cell (RPGC) that also appeared multi-nucleated. This cell also
stained positive for fibroblast markers. The purpose of this study was to better
characterize this RPGC as a fibroblast through use of antibodies to fibroblasts and other
cells typically found in the interfacial membrane.
We took interfacial membrane and associated granuloma tissue from five patients
undergoing revision joint surgery due to osteolysis. This tissue was frozen sectioned onto
slides and stained using fluorescent antibodies and observed using confocal microscopy.
The presence of fluorescence was evaluated for intensity and localization with the RPGC.
The results of this study showed that the RPGC was negative for the osteoclast
marker RANK and TRAP however, it was positive for the receptor to calcitonin. The
RPGC stained positive for D7-fib, 5B5,and OPG while staining negative for osteocalcin
and VDR. We were also able to demonstrate that this RPGC stains positive for
cytomegalovirus and TACE.
The data suggests that the RPGC is of fibroblast origin while sharing similarities

with osteoblasts and osteoclasts. It also appears that this cell is multi-nucleated and that
its positive staining with CMV may offer an explanation as to the formation of a multinucleated fibroblast. Finally the positive expression of TACE co-localized with RANKL
suggests that this RPGC is a source of RANKL to a widespread area of the IFM.

INTRODUCTION
Previous work done by our laboratory has identified a RANKL-positive
multinucleated giant cell (RPGC) of fibroblast origin in the periprosthetic membrane of
total joint arthroplasty patients. This cell has been observed in every interfacial
membrane thus far studied, (approximately n = 20). RANKL is typically produced by
osteoblasts, bone marrow stromal cells, and transiently by activated lymphocytes. The
RANKL/RANWOPG signaling system is a potent activator of bone reabsorption and
high levels of RANKL detected in the interfacial membrane have shaped the idea that the
interfacial membrane is not only a characteristic of periprosthetic osteolysis but also a
mediator of it. The cell source of RANKL in the interfacial membrane is still unclear due
to the absence of osteoblasts, however, recent data indicating IFM fibroblasts are capable
of expressing RANKL and facilitating osteoclastogenesis in vitro has renewed interest in
exploiting RANKL as a therapeutic target. Fibroblasts cultured out of the membrane and
tissue have been shown to be positive for RANKL mRNA through RT-PCR [52]. The
identification of a multinucleated RPGC expands the scope of RANKL-mediated
osteolysis and thus this RPGC is of great interest. The purpose of this study was to better
characterize the RPGC as being definitively a fibroblast or not. In addition to staining for
fibroblast markers we stained for osteoblast markers and osteoclast markers. Sections
from each patient's tissue were also stained with the light stain tartrate resistant acid
phosphatase (TRAP) to demonstrate the presence of mature osteoclasts in each interfacial
membrane sample. TRAP is an enzyme produced by mature osteoclast and osteoclast like
cells and TRAP stain is a relied on method of detecting osteoclasts using light
microscopy [ 19,521.

This study involved five different interfacial membrane samples retrieved from
five different patients undergoing revision joint surgery. The samples were collected over
a period of time from June 2005 to March 2006. The membranes and associated tissue
were collected from patients determined to have bone loosening around their prosthesis in
the absence of infection as determined by clinicians. This panel of patients was not
controlled for type of joint being revised and is a mix of hip and knee revisions.
However, aseptic osteolysis has been demonstrated in both joints and formation of the
IFM and granuloma is the common end result of the disease in each case [42]. The
patients consisted of two males and three females and the ages ranged from 67 - 83 at the
time of surgery. This study will attempt to determine whether or not the RPGC is of
fibroblast origin or not using tissue from a varied cross-section of patients undergoing
revision joint surgery due to aseptic osteolysis.

MATERIALS AND METHODS
Tissue preparation

Tissue was obtained from patients undergoing revision hip or knee surgery. The
IFM and granuloma tissue was kept at 4' C following removal from the patient. The
tissue was then embedded in OCT compound (Tissue-Tek) and frozen at -20°C until it
was sectioned. The sections were made at 12 microns on a microtom frozen section cutter
and melted on to superfrost microscope slides (Fisher Scientific). Frozen sections were
kept at -20°C until stained.
Antibody Staining

Frozen sections were fixed using ice cold 100% methanol for 60 seconds and then
washed with PBS. The slides were blocked and washed for ten minutes using a 3% goat
serum and 0.1% triton PBS solution to decrease non-specific binding. Antibodies were
diluted in PBS. Primary antibodies were diluted 1:50 and secondary antibodies were
diluted 1:200 in PBS. Following each incubation the slides were washed 5 times with
PBS to remove non-specific binding. All sections were stained with Hoechsl34580
(Molecular Probes) stain diluted 1:200 in PBS. Table 3 summarizes the information
about each antibody used in this study.
Analysis of Immunolabeling

Slides were observed using a Carl Zeiss LSM 5 10 Meta confocal imaging
microscope. The lasers used for analysis were the 405nrn diode laser, a 488nm argon
laser, and a 543nm helium neon laser. All pictures were taken using a 63x oil immersion
objective. In each case the characteristic intense RANKL staining was used to target cells
for analysis. The sections were analyzed using FITC fluorescence to locate the

characteristic intense RANKL staining. Once located the examples were checked with
light microscopy to ensure that a distinct cell was present. In all examples a Hoechst
nuclear stain was used to determine if examples were multi-nucleated or not as this was a
characteristic of previously examined cells.

TRAP staining
An IFM tissue section from each patient was stained for TRAP using a kit
obtained from Sigma Aldrich. These sections were then counterstained with hemotoxylin.
The sections were observed for TRAP' cells using a 40x and a 100x objective on a
standard light microscope connected to a digital camera. Upon observation of the sections
giant cells were observed that appeared similar to Differential Interference Contrast
(DIC) images taken of the RANKL producing cell during confocal microscopy. Images
of these giant cells were captured in addition to TRAP positive cell images.

Table 3: Antibodies used in CMV and TACE study
The table summarizes the information on the antibodies used in this study including their
name, host animal, fluorescent secondary and supplier.

Primary antibody

primary host
animal

CMV monoclonal

mouse

RANKL polyclonal

goat

RANK polyclonal

rabbit

TACE monoclonal

rabbit

D7-fib monoclonal

mouse

OPG polyclonal

rabbit

5b5 monoclonal

mouse

CTR monoclonal
Osteocalcin
polyclonal

mouse

VDR polyclonal

rabbit

rabbit

Secondary antibody
543 chicken antimouse

.

488 donkey anti-goat
543 chicken antirabbit
543 chicken antirabbit
543 chicken antimouse
543 chicken antirabbit
543 chicken antimouse
543 chicken antimouse
543 chicken antirabbit
543 chicken antirabbit

Supplier
Chemicon International
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Serotec Biological
Gene Tex
Santa Cruz
Biotechnology
Dako Corporation
Serotec Biological
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology

RESULTS
Staining of RPGC with RANK and CTR antibodies
Besides foreign body giant cells (FBGC) in the IFM, another type of multinucleated cell that has been well characterized as being in the interfacial membrane is an
osteoclast [5, 551. Osteoclasts mediate bone reabsorption in the body through the
breakdown of the bone matrix and the release of calcium. Osteoclasts express myeloid
antigen surface integrins as they are of myeloid lineage, such as CD68, CTR and TRAP.
The cell membrane bound receptor RANK is seen on pre-osteoclastic cells. Signaling
through this receptor by RANKL causes osteoclastic differentiation and osteoclast
activation. Additionally, the signaling of the RANK receptor provides an anti-apoptotic
signal to mature osteoclasts. For this reason RANK is not only observed on preosteoclastic myeloid cells such as monocytes but also on mature osteoclasts. The sections
were stained with two antibodies directed against osteoclastic antigen to determine if the
RPGC was simply an osteoclast. The first antibody was against RANK. This antibody
showed little to no staining in the section and did not stain the RPGC (figure 9A).
The second osteoclastic antigen we targeted was CTR. The CTR is expressed on
osteoclasts and when bound by calcitonin it mediates a decrease in bone reabsorption. It
is a good detector of osteoclasts in the IFM because while cells of the kidney and nervous
system express CTR no other cell in and around the bone system expresses CTR. The
staining of RANKL with CTR demonstrated significant binding of the CTR antibody
with the RPGC. There was also signifigant staining of the surrounding tissue by the CTR
antibody as can be seen in figure 9B.

Staining of RPGC with 5B5 and D7-fib antibodies

Previous studies have indicated that this giant RANKL producing cell stains
positive for fibroblast markers [47]. In order to confirm this result and classify this RPGC
as being fibroblast-like, we stained the tissue sections with the cell surface marker, D7fib. In a case study done previously, we have seen that D7-fib co-localizes well with the
RANKL antibody staining pattern and well approximates the shape of the RANKL
producing cell. That result was observed again in this study. The D7-fib antibody stained
well with the RANKL producing cell and localized well with the outline of the RANKL
producing cell. The staining of D7-fib antibody was similar in pattern to that of the

RANKL antibody. These two antibodies co-localized very well as seen in figure 10A.
In previous work on the multi-nucleated RANKL giant cell, we have seen D7-fib
antibody positively binding to the RPGC and it was observed again in this study. In order
to confirm this result and more conclusively determine that this cell was indeed a
fibroblast we stained the sections with 5B5 antibody. 5B5 is an antibody that binds to the
intracellular 4-prolyl-hydroxylase enzyme necessary for the production of collagen and
thus is a good marker for identification of fibroblasts. 5B5 is used often in studies
involving the IFM to identify fibroblasts [52]. The staining of the 5B5 antibody showed a
splotchy pattern of staining with points of intense fluorescence and points of decreased
fluorescence as compared to D7-fib. However, the staining of 5B5 antibody
approximated the shape of the RANKL producing cell as denoted by RANKL staining.
Despite a varied intensity along the RPGC for 5B5, the overall staining of 5B5 still gave
intense fluorescence and was considered a positive result (figure 10B)

Staining of the RPGC with VDR, osteocalcin, and OPG

The expression of RANKL by osteoblasts is well documented and occurs under
physiological conditions [8,28]. The expression of RANKL by osteoblasts is up
regulated by parathyroid hormone in response to low blood calcium level. The expression
of RANKL by osteoblasts leads to an increase in osteoclast formation and activation.
This increase in osteoclast activation will in turn increase bone reabsorption and release
more calcium and phosphate into the blood. The fact that osteoblasts express RANKL
made it necessary to determine if the RPGC was positive for antibody staining specific to
osteoblasts.
The first osteoblast-specific antibody used was against the vitamin D receptor
(VDR). Vitamin D is responsible for-increasingcalcium levels in the blood through
action on the GI tract, kidneys, and bone. The presence of VDR is most highly seen in the
villi of the duodenum, distal tubule cells of the kidney, and cells of the bone specifically
osteoblasts and osteocytes. The active form of vitamin D, calcitriol, is involved in
mediating osteoblastic expression of RANKL which will increase osteoclastogenesis and
increase blood calcium levels. While calcitriol is seen in most all cell types in the body it
is expressed only in low levels in areas other than the intestine, kidneys, and skeletal
system. The staining of VDR with the RANKL giant cell revealed weak staining of VDR
antibody on the RPGCs (figure 11A). This low level of staining indicates that VDR is
undetectable or very low in the RPGC.
The non-collagenous protein osteocalcin is produced by osteoblasts in response to
calcitriol. It is a protein unique to bone tissue that causes the proper deposition of
phosphate and calcium in the osteoid during new bone formation. The staining of the

IFM tissue samples with osteocalcin revealed rather intense staining over the entire
tissue. However, the important observation was that the RPGC demonstrated only limited
staining with osteocalcin antibody as compared to the rest of the tissue. In fact the cell
was relatively absent of osteocalcin staining and certainly showed a decreased intensity
when compared to the surrounding tissue (figure 11B). These data would suggest that the
RPGC is negative for osteocalcin.
The third part of the RANKLIRANK signaling triad is the molecule
osteoprotegrin (OPG). OPG is expressed in similar cell types as RANKL, such as
osteoblasts, however, OPG gene expression can be reciprocal to that of RANKL. The
function of OPG is the inhibition of RANKL signaling through blocking of the
interaction between RANKL and RANK. OPG is a soluble decoy receptor of RANKL
typically expressed as regulatory measure by RANKL producing cells. The antibody
staining for OPG showed intense co-localization with the RPGC. The antibody for OPG
approximated the same staining pattern as the RANKL antibody and co-localized with
the RANKL antibody as seen in figure 11C. It seems likely that this cell is secreting both
OPG and RANKL.
Staining of the RPGC with TACE and CMV antibodies

The presence of a multi-nuclear fibroblast is an interesting phenomenon that is
certainly not normal under physiological conditions in the body. In order to give some
explanation as to how a multi-nuclear fibroblast might form we investigated the
possibility of viral mediated cellular fusion. Based on information from a virologist
associated with our laboratory we determined that human cytomegalovirus (CMV) might
be a likely candidate as a mediator of fibroblast cell fusion. CMV has been demonstrated

in vitro and in vivo to cause the fusion of fibroblasts into multinuclear giant cells [50].
Clinical observations of CMV infected tissues have revealed swollen multi-nuclear cells
that could be similar to the giant cell we observe in the IFM. The tissue sections were
thus stained with a CMV monoclonal antibody to determine at least if these cells were
CMV antibody positive. The staining pattern showed co-localization of the CMV
antibody with the RPGC in all examples looked at. The signal from the CMV antibody
was very strong in most of the examples and certainly present in all of them (see figure
12 A and B). The staining was not always consistent with the RANKL outline of the
RPGC as it sometimes was more localized to the nuclei of the cell however the CMV
antibody was definitively attached to the cell in each case.
The enzyme TNF-alpha converting enzyme (TACE) has been implicated in the
formation of soluble RANKL. The enzyme is membrane bound and clips of the RANKL
molecules from the cell expressing it and releases them into the extra-cellular
environment. Recent studies have shown that this soluble RANKL is in fact active and
capable of inducing osteoclastogenesis [61-631. The presence of TACE co-localized with
the RPGC would indicate that this cell that so highly expresses RANKL is capable of
mediating pro-osteoclastogenic effects to a much greater population of cells than those
immediately surrounding it. When the tissue sections were stained with TACE it was
observed that there was intense staining and co-localization of the TACE antibody with
RPGC. When compared to the other assays done in this study TACE represented the
highest intensity of staining and thus antibody binding of all the antibodies used other
than RANKL (figure 12 C). These data depict the RPGC as TACE positive and as a colocalized signal with RANKL.

TRAP staining of IFM
In all IFM tissue samples examined, TRAP positive cells were observed. TRAP is
an enzyme produced by osteoclasts as they mature and after they become activated. The
significance of the TRAP stain indicates the osteoclasts are present in the membrane.
However, due to the method of TRAP staining which requires counter staining with
hematoxylin we observed that multi-nucleated TRAP negative cells could be observed
using the light microscope. The observation that RPGCs stained negative for TRAP is
consistent with the concept that RPGCs are non myeloid entities (figure 13)

Figure 9: The staining of the RPGC with RANK and CTR antibodies
Figure 9A: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows RANK antibody staining with anti-rabbit secondary (red). Panel
c, shows a composite picture of the two antibody stains with Hoechst nuclear stain (blue).
Image taken at 630x. (BJ020)
Figure 9B: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the CTR antibody staining with anti-mouse secondary (red).
Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear stain
(blue). Image taken at 630x. (BJ022)

Figure 10: Staining of the RPGC with D7-fib and 5b5 antibodies
Figure 10A: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the D7 antibody staining with anti-mouse secondary (red). Panel
c, shows a composite picture of the Wo antibody stains with Hoechst nuclear stain (blue).
Image taken at 630x. (BJO 18)
Figure 10B: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the 5B5 antibody staining with anti-mouse secondary (red). Panel
c, shows a composite picture of the two antibody stains with Hoechst nuclear stain (blue).
Image taken at 630x. (BJ020)

Figure 11: Staining of the RPGC with VDR, osteocalcin, and OPG
anti bodies
Figure 11A: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the VDR staining with anti-mouse secondary (red). Panel c,
shows a composite picture of the two antibody stains with Hoechst nuclear stain (blue).
Image taken at 630x. (BJ005)
Figure 11B: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the osteocalcin antibody staining with anti-mouse secondary
(red). Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear
stain (blue). Image taken at 630x. (BJ005)
Figure 11C: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows OPG antibody staining with anti-rabbit secondary (red). Panel c,
shows a composite picture of the two antibody stains with Hoechst nuclear stain (blue).
Image taken at 630x. (BJ018)

Figure 12: Staining of the RPGC with CMV and TACE antibodies.
Figure 12A: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the CMV antibody staining with anti-mouse secondary (red).
Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear stain
(blue). Image taken at 630x. (BJ021)
Figure 12B: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the CMV antibody staining with anti-mouse secondary (red).
Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear stain
(blue). Image taken at 630x. (BJO 18)
Figure 12C: Panel a, shows the RANKL antibody staining with anti-goat secondary
(green). Panel b, shows the TACE antibody staining with anti-mouse secondary (red).
Panel c, shows a composite picture of the two antibody stains with Hoechst nuclear stain
(blue). Image taken at 630x. (BJ020)

Figure 13: TRAP staining of IFM
Panel A, shows the multinucleated cell stained with hematoxylin at 400x (BJ020)
Panel B, shows the presence of TRAP' cells in the IFM at 1000x (BJ022)

DISCUSSION
The formation of the interfacial membrane and granuloma is a common end
product of all aseptic osteolysis. RANKL is a potent activator of bone reabsorption. We
have studied this membrane to identify the cell source of the RANKL and through doing
this we observed large multi-nuclear cells that express very high levels of RANKL.
RANKL is typically produced by osteoblasts however in the interfacial membrane
RANKL has been demonstrated to be expressed by fibroblasts 19, 521. The purpose of
this study was to distinguish this RPGC seen in all IFM samples as being definitively of
fibroblast origin. Additional assays were done to determine a possible hypothesis
explaining the formation of this cell and how it might be important in the aseptic
osteolysis story. The study was done using tissue obtained from five different patients
undergoing revision joint surgery. The tissue was subjected to antibody staining and then
confocal microscopy. Several tissue sections were stained with TRAP and evaluated
using light microscopy.
The first step in defining this RPGC was to eliminate possibilities of other cells it
could be. Multinuclear giant cells are seen in the interfacial membrane in the form of
osteoclasts. Osteoclasts do not express RANKL however they do express RANK and if
there were soluble RANKL present that was bound to this cell it could be possible for an
osteoclast to stain positive for RANKL [14]. Thus it was necessary to stain this RPGC
with osteoclast markers to determine whether or not it was an osteoclast.
The first antibody was directed against the membrane bound receptor RANK.
RANK is a member of the TNF receptor superfamily and when bound it interacts with
the protein TNF Receptor Associated factor (TRAF) to activate NF-KB. RANK has been

shown recently to be expressed on pre-osteoclastic cells and its activation leads to the
formation and activation of osteoclasts [14]. RANK is expressed on most cells of myeloid
lineage. The antibody for RANK was a polyclonal antibody raised in rabbits against
amino acids 3 17-616 mapping to the C-terminus of human RANK. The staining with
RANK showed no co-localization with the RANKL producing cell and no intensity. The
absence of RANK on the RANKL cell gives evidence to the fact that it is not of myeloid
lineage and also is not an osteoclast.
To further evaluate the possibility that the RPGC was an osteoclast, tissue
sections were also stained with an antibody to CTR. The CTR molecule is expressed in
kidney cells, central and peripheral nervous system cells and osteoclasts. The CTR is a
cell surface membrane protein with seven transmembrane regions coupled to a G protein.
The binding of calcitonin to its CTR on osteoclasts causes a decrease in their activity and
a corresponding decrease in bone reabsorption. The molecule calcitonin is a 32 amino
acid peptide generated from parafollicular cells in the thyroid gland. The purpose of
calcitonin is to regulate calcium and phosphorus levels in the blood. It was a monoclonal
antibody raised in mice against a cytoplasmic epitope of the seven transmembrane region
of the receptor. The positive binding of CTR antibody to the RPGC does seem to weaken
the argument for this cell not being an osteoclast. However, the failure of the cell to bind
with RANK and failure of this cell to bind Ber-Mac3 in previous experiments (data not
shown) would suggest that this cell is not of myeloid lineage as an osteoclast would be.
Furthermore, there has been evidence recently that foreign body giant cells express CTR
though are not osteoclasts [55,64, 651. It is possible that this RPGC shares characteristics
with other giant cells found in the interfacial membrane though its failure to bind myeloid

markers make it unlikely to be a foreign body giant cell. The expression of RANKL,
therefore, is not a characteristic of osteoclasts or foreign body giant cells [65].
The antibodies designed to denote the cell as fibroblast were 5B5 and D7-fib. 5B5
is an antibody designed to bind to the proylyl4-hydroxylase protein that is seen in
fibroblasts actively synthesizing collagen. Proylyl4-hydroxylase is an enzyme that is
central to collagen production. It catalyzes the formation of 4-hydroxyproline by
hydroxylation of prolines in X-pro-Gly sequences on collagens, this process of course
being essential to the formation of collagen triple helix. The antibody used in this study
was monoclonal for proylyl4-hydroxylase and raised in mice against human antigen.
This antibody co-localized well with the RPGC in spotty though distinct pattern that
approximated the shape of the entire cell. The cell that both RANKL and 5B5 stained
contained multiple Hoechst stain positive spots which would indicate nuclei. The staining
pattern seen in this cell would indicate that the RPGC is positive for proylyl4hydroxylase which would certainly point to it being a fibroblast.
The second fibroblast marker used was D7-fib. D7-Fib is an antibody that
recognizes a 112 kD molecule expressed on the cell surface of human fibroblasts and
epithelial cells. The antibody does have the ability to bind to peripheral blood myeloid
cells and in some cases smooth muscle. However, in tissue it primarily targets fibroblast
cells and epithelial cells. The antibody used in this study was a monoclonal antibody for
D7-fib raised in mice. The staining of D7-fib with the RPGC was very good at
approximating the shape of the cell and had a similar staining pattern to the RANKL
antibody however in some examples it did lack intensity in its staining. Despite this
observation, the similar staining of the RANKL antibody and the D7-fib antibody would

indicate this cell is positive for the D7-fib antigen and is of fibroblast origin. When taken
in concert with the observations of the 5B5 staining, it seems very likely that this cell is a
fibroblast. As with the previous stains the RANIU staining cell had multiple nuclei in it.
This is characteristic of these cells and was used in addition to RANKL expression to
target these cells for analysis.
The expression of RANIU is not a uniquely an osteoblast characteristic, however,
in the bone system they are the dominant producer of it. Osteoblasts produce high levels
of RANKL in response to parathyroid hormone and calcitriol. Studies of the composition
of the interfacial membrane have reveled that very few osteoblasts are present there [12,
421. However, this RPGC is also relatively rare in the tissue which would make it
multi-nucleated RANKL expressing cell. In
conceivable that it was an oste~blast~like
order to test this hypothesis the tissue sections were stained with three different
antibodies to antigen expressed by osteoblasts.

VDR is typically expressed on distal tubule kidney cells, villi of the duodenum,
osteocytes and osteoblasts in high concentration with low concentrations seen in most
other cell types of the body. The purpose of the VDR is to mediate the effects of
calcitriol. The primary function of calcitriol is to maintain homeostatic levels of calcium
in the blood. Calcitriol functions on the cells of the duodenum to increase calcium
absorption from the digestive track. Similarly when calcitriol acts on the osteoblasts it
increases their production of RANKL for the purposes of increasing bone reabsorption
which increases calcium and phosphate levels in the blood. The VDR antibody used was
a rabbit polyclonal raised against the C-terminus of VDR in rats. This antibody shows
significant cross-reactivity with mice and humans. Calcitriol can up or down regulate

cells responses including proliferation, differentiation, and calcium homeostasis by acting
at the level of gene transcription. The limited staining with VDR antibody indicated the
RPGC is distinct from an osteoblast, which would contain a strong signal for VDR. These
data suggest that this RPGC expresses low levels of VDR, if any at all.
Osteocalcin is a 5800 MW extrahepatic vitamin K dependent protein uniquely
expressed by osteoblasts. Osteocalcin is one of the most abundant proteins in the body
and the second most abundant protein in the skeletal system next to collagen. Osteocalcin
functions in facilitating the binding of calcium ions and hydroxyapatite together to be
deposited on the collagen matrix of developing bones. Osteocalcin is a highly conserved
46-50 amino acid single chain protein that contains three vitamin K-dependant gammacarboxyglutamic acid residues. The antibody was a polyclonal antibody raised in rabbits
against the full chain of human osteocalcin. The staining pattern with osteocalcin showed
intense staining of the surrounding interfacial membrane. The stain however showed only
small portions of co-localization with the RANKL producing giant cell. The staining was
in fact diminished on the giant cell with regards to the surrounding tissue. The intense
staining of the surrounding tissue can possibly be attributed to either high level of
osteocalcin in the cells of the IFM or a potentially high levels of bone reabsorption as
would be noted in osteolysis. The staining seen in this example could be representative of
fragments of osteocalcin being trapped in the surrounding tissue of an area where high
levels of bone reabsorption are taking place; the IFM is such a tissue. Additionally, the
osteocalcin antibody was raised against the entire osteocalcin molecule which would
make it possible to bind to fragments of the original protein that have become trapped in
the tissue. The RPGC did have some binding with the osteocalcin antibody but it was

reduced compared to that of the surrounding tissue. This indicates that this RPGC is
negative for osteocalcin production.
The final antibody used that was specific to an osteoblast antigen was against
OPG. OPG is the abbreviation of the protein osteoprotegrin and is also known as
osteoclastic inhibition factor (OCIF). OPG is expressed by RANKL producing cells such
as osteoblasts as a form of self regulator of RANKL signaling. The OPG antibody used in
this study was an anti-human polyclonal raised in rabbits against amino acids 153-401 of
OPG. The staining with OPG showed some intense staining on the RPGC and colocalized well with the cell. In some examples this stain appeared to be more intense
around the nuclei of the cell than the RANKL stain, however, it was consistently seen on
the RPGC. These data provide evidence that the RPGC could be of osteoblast origin.
However, it has been well documented that fibroblasts isolated from the interfacial
membrane in addition to expressing RANKL are capable of expressing OPG [55]. OPG
production and RANKL production are consistently detected in fibroblasts removed from
the interfacial membrane [52]. To this effect, the staining pattern of the OPG stain does
not strengthen or weaken the argument that this multi-nucleated cell is fibroblast-like. It
simply strengthens the argument that this cell shows similar properties to other RANKL
producing cells.
In addition to the fluoro-stains to characterize the RPGC as either osteoblast or
fibroblast, we stained IFM tissue sections from all patients with a CMV antibody. This
was a result of a previous case study done in this laboratory where CMV antibody bound
successhlly to the RPGC. The positive CMV antibody staining in one patient facilitated
the need to repeat the experiment in multiple patients in an effort to demonstrate the

presence of CMV in this cell. It has been documented that certain viruses of the herpes
family can cause fusion of cells leading them to become multinuclear. One of these
viruses in particular is cytomegalovirus (CMV) [49]. As stated previously, CMV
infection has the capability of causing fibroblasts to fuse and form giant multinucleated
cells [50]. We obtained a CMV monoclonal antibody raised in mice with reactivity to
human IE1-72, and IE2-86 CMV epitopes. IE1 and IE2 are early non-structural antigens
of CMV infected cells that can be detected after 1 hour of infection, but can be detected
throughout the entire CMV infection cycle. Like most herpes virus family members,
CMV goes through cycles of latency and active replication and like most other herpes
viruses there is a high infection rate in the population and the immune system can never
quite clear the disease [49]. The staining for CMV very well co-localized the RANKL
cell and demonstrated some intensity of staining. These data show that the RANKL cell
is CMV antibody positive. Although more testing will need to be done to determine
CMV's involvement in the formation of this cell, the positive antibody staining certainly
provides a plausible hypothesis that CMV infection of these fibroblast-like cells in the
IFM causes them to fuse forming multi-nuclear cells that produce high levels of RANKL.
RANKL is a membrane bound molecule that interacts with RANK to mediate
osteoclastogenesis. There has been evidence recently that soluble RANKL molecules
may be a viable source of the RANKL signal and thus bypass the essential need for the
cell to cell interaction that is modeled in bone tissue. Soluble RANKL could allow a
RANKL producing cell to mediate its effects over a much broader area of tissue than
those cells immediately adjacent to it. The formation of soluble RANKL has been
associated with the enzyme TACE, which stands for TNF-alpha converting enzyme.

TACE, also known as cd156b, is a membrane-bound metalloprotease disintegrin that
belongs to the mammalian ADAM family. TACE has the ability to clip the RANKL
molecule from the cellular membrane to which it is bound and allow it to be secreted into
the extracellular environment [66,67]. This secreted RANKL has recently been
characterized as being capable of inducing osteoclastogenesis and stimulating bone
reabsorption [61,62]. The TACE antibody was raised in rabbits against amino acids 807-

823 at the C-terminal end of human TACE. The antibody staining of TACE was the most
intense staining seen in this study next to RANKL. It co-localized exceptionally well with
the RANKL antibody and gave a very intense signal. These data strongly suggest that
these giant RANKL producing cells are also producing TACE. The co-production of
TACE and RANKL would lead to a scenario where you have an abundant production of
soluble RANKL which would allow this cell to disperse pro-bone reabsorbing signals
over a wide area in the membrane.
The staining of the IFM granuloma tissue with TRAP demonstrated the
identification of multiple TRAP' cells in the IFM tissue samples. TRAP is produced by
osteoclasts both prior and after they reach maturity. The presence of TRAP' cells
indicates the presences of osteoclasts in the interfacial membrane. Additionally, as a byproduct of the TRAP staining which required hematoxylin counter-staining we were able
to observe the giant cells under a light microscope without the aid of immunofluoresence.
The RPGCs were not positive for TRAP which when coupled with the antibody stain
against RANK, only serve to strengthen the argument that these multi-nucleated cells are
not osteoclasts but rather some other type of cell. Based on the antibody staining and
composition of the membrane it would seem likely that this cell is a fibroblast.

Additionally, the visualization of this cell using a different technique than confocal
microscopy gives validity to the cell's presence in the IFM and insight into its
morphology.
More detailed imaging, such as electron microscopy, will be required to
determine if it is really a multi-nucleated cell or simply an aggregate of cells close
together. However, the fact remains that this structure produces a high level of RANKL
and its antibody staining is consistent with it being a fibroblast. Electron microscopy is
needed to determine whether the cell is multinucleated or not and at present a sample is
being prepared for transmission electron microscopy. The RANKL producing giant cell
seen in the interfacial membrane stained positive for CMV antibody. The infection of this
cell with CMV could lead to an explanation of how it hses. This cell appears to be a
strong source of RANKL in the interfacial membrane and as such could be a potent
activator of osteoclastogenesis and cause osteolytic bone reabsorption. This is supported
by the evidence of high levels of TACE on the giant cell. Should this giant cell be
producing high levels of RANKL and high levels of TACE then it is possible for this cell
to mediate pro-osteoclastogenic events in a wide area of tissue. The high level of
RANKL and TACE being expressed on this cell would indicate that while rare in the
tissue this cell can be an important activator of osteoclastogenesis and osteoclast
activation leading to osteolysis. Future research efforts in regards to this cell will involve
attempts to isolate this RANKL producing cell fiom the interfacial membrane using laser
capture microscopy with the intention of performing RT-PCR on it. Analysis of the RNA
present in the cell through RT-PCR will give insight into the genes in the cell actively
being transcribed. Analysis of these transcripts can give insight into the role TACE plays

in the RPGC's effectiveness as a mediator of osteolysis. The RNA analysis will also be
able to determine what role CMV plays in the formation of this cell. Should it be
determined that this RPGC is a potent mediator of aseptic osteolysis and it is formed by
CMV than it could lead to new clinical options in the prevention of osteolysis. Currently,
preventive anti-viral drugs are given to graft recipients to combat CMV and potentially
this could become an anti-osteolysis therapy [68]. Although due to the toxic nature of
these drugs this seems like an unlikely option. The most promise for osteolysis therapy
would seem to lie with anti-RANKL treatments as these are already in clinical trials.

GENERAL CONCLUSIONS
The data from the two studies presented in this thesis demonstrate that there is a
large structure in the IFM that is RANKL positive and multi-nucleated. The RPGC was
not of myeloid origin as demonstrated by failure to bind RANK or BerMac3. The RPGC
was positively identified using fibroblast-specific antibodies, D7-fib and 5B5. Thus, these
data support the hypothesis that the RPGC is a multi-nucleated cell and fibroblast in
origin. However, the binding of the RPGC with VDR, RANKL, and osteoclacin suggest
that this RPGC shares some characteristics with osteoblasts. The negative TRAP staining
indicates that RPGCs are not an osteoclast however the binding of CTR demonstrates this
RPGC does have a similarity with osteoclasts and foreign body giant cells. The positive
binding of inflammatory cytokines to this cell provide evidence that RPGCs mediate
inflammation in the IFM through cytokine production or responds to the inflammation
through the high concentrations of cytokines bound to it. This RPGC also showed a
positive identification for CMV and TACE. We hypothesize that this RPGC is a multinucleated fibroblast formed through infection with CMV and is a potent activator of bone
reabsorption beyond the cells adjacent to it through the co-localization of TACE and
RANKL. The intense inflammation seen in the IFM makes it a unique environment
where CMV could come out of latency and mediate fibroblast fusion leading to formation
of the RPGC.
Confirmation of this hypothesis could lead to future preventative therapies of
osteolysis to involve both anti-RANKL treatments and anti-viral treatments.
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